These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 27264755)

  • 1. Development of a Synthetic Heparin Pentasaccharide: Fondaparinux.
    Walenga JM; Fareed J; Jeske WP; Bıck RL; Samama MM
    Turk J Haematol; 2002 Jun; 19(2):137-50. PubMed ID: 27264755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent.
    Walenga JM; Jeske WP; Samama MM; Frapaise FX; Bick RL; Fareed J
    Expert Opin Investig Drugs; 2002 Mar; 11(3):397-407. PubMed ID: 11866668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux).
    Samama MM; Gerotziafas GT
    Thromb Res; 2003 Jan; 109(1):1-11. PubMed ID: 12679126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical use of Fondaparinux: A synthetic heparin pentasaccharide.
    Zhang Y; Zhang M; Tan L; Pan N; Zhang L
    Prog Mol Biol Transl Sci; 2019; 163():41-53. PubMed ID: 31030756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short- and long-acting synthetic pentasaccharides as antithrombotic agents.
    Walenga JM; Jeske WP; Fareed J
    Expert Opin Investig Drugs; 2005 Jul; 14(7):847-58. PubMed ID: 16022574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemistry and clinical pharmacology of new anticoagulant agents.
    Samama MM; Gerotziafas GT; Elalamy I; Horellou MH; Conard J
    Pathophysiol Haemost Thromb; 2002; 32(5-6):218-24. PubMed ID: 13679646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The synthetic pentasaccharide fondaparinux: first in the class of antithrombotic agents that selectively inhibit coagulation factor Xa.
    Petitou M; Duchaussoy P; Herbert JM; Duc G; El Hajji M; Branellec JF; Donat F; Necciari J; Cariou R; Bouthier J; Garrigou E
    Semin Thromb Hemost; 2002 Aug; 28(4):393-402. PubMed ID: 12244487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fondaparinux, the first selective factor Xa inhibitor.
    Turpie AG; Eriksson BI; Lassen MR; Bauer KA
    Curr Opin Hematol; 2003 Sep; 10(5):327-32. PubMed ID: 12913785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fondaparinux: basic properties and efficacy and safety in venous thromboembolism prophylaxis.
    Bauer KA
    Am J Orthop (Belle Mead NJ); 2002 Nov; 31(11 Suppl):4-10. PubMed ID: 12463577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fondaparinux for prevention of venous thromboembolism in major orthopedic surgery.
    Tran AH; Lee G
    Ann Pharmacother; 2003 Nov; 37(11):1632-43. PubMed ID: 14565815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heparin pentasaccharide.
    Gallus AS; Coghlan DW
    Curr Opin Hematol; 2002 Sep; 9(5):422-9. PubMed ID: 12172461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fondaparinux (Arixtra): a new anticoagulant.
    Giangrande PL
    Int J Clin Pract; 2002 Oct; 56(8):615-7. PubMed ID: 12425373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents - the selective factor Xa inhibitors.
    Bauer KA; Hawkins DW; Peters PC; Petitou M; Herbert JM; van Boeckel CA; Meuleman DG
    Cardiovasc Drug Rev; 2002; 20(1):37-52. PubMed ID: 12070533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fondaparinux: a Factor Xa inhibitor for antithrombotic therapy.
    Turpie AG
    Expert Opin Pharmacother; 2004 Jun; 5(6):1373-84. PubMed ID: 15163281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factor Xa is highly protected from antithrombin-fondaparinux and antithrombin-enoxaparin when incorporated into the prothrombinase complex.
    Brufatto N; Ward A; Nesheim ME
    J Thromb Haemost; 2003 Jun; 1(6):1258-63. PubMed ID: 12871328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fondaparinux sodium.
    Reverter JC
    Drugs Today (Barc); 2002 Mar; 38(3):185-94. PubMed ID: 12532174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Hirsh J; Raschke R
    Chest; 2004 Sep; 126(3 Suppl):188S-203S. PubMed ID: 15383472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in anticoagulation therapy: the role of selective inhibitors of factor Xa and thrombin in thromboprophylaxis after major orthopedic surgery.
    Andersen JC
    Semin Thromb Hemost; 2004 Dec; 30(6):609-18. PubMed ID: 15630666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New pentasaccharides for prophylaxis of deep vein thrombosis: pharmacology.
    Bauer KA
    Chest; 2003 Dec; 124(6 Suppl):364S-370S. PubMed ID: 14668419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From heparins to factor Xa inhibitors and beyond.
    Alban S
    Eur J Clin Invest; 2005 Mar; 35 Suppl 1():12-20. PubMed ID: 15701143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.